en 12 Diciembre 2016
  • Primer país del mundo que reconoce el uso médico del ozono.
  • La primera decisión fue tomada por el gobierno griego en 1991.
  • Una segunda decisión fue adoptada en el 2014.
  • La terapia de ozono se puede aplicar a todas las especialidades y las enfermedades en las que pueda ser usada, tanto en el sector públicos como en el privado.

      1991. Decreto Presidencial 157 de 1991 (Gaceta Oficial 157/A /1991)

Decreto sobre “el aumento de los ingresos derivados de las visitas médicas, así como las prácticas médicas y dentales”. Detalla la lista de terapias y cuánto se debe cobrar por cada uno de ellas.

 

La ozonoterapia está incluida en el capítulo de Cirugía Vascular (sección II): Terapia intraarterial de ozono terapia (párrafo 48) y ozonoterapia externa (Párrafo 62). Esto significa que estos dos procesos que utilizan el ozono médico fueron autorizados, ya que se incluyeron en la lista de las prácticas médicas y el precio a pagar por ellas.

 

     2014. Ministerio de Salud y la Dirección General de Servicios de Salud. Número de protocolo: Y4a / oil.75108 29 de agosto de 2014

El Ministro de Salud el 29 de agosto 2014 amplió el ámbito de aplicación de la ozonoterapia a todas las especialidades y enfermedades, tanto en el sector público como privado.

 

El ministro de Salud, se refiere explícitamente a la inclusión de la terapia de ozono en el Boletín Oficial 157/A /1991, relativo a las terapias médicas.  Hace referencia a la autohemoterapia mayor y menor, a las inyecciones intramusculares e intraarticulares de ozono, especificando “que son métodos conocidos en el mundo que se aplican no sólo en enfermedades linfáticas, sino que se han propuesto y recomendado para todas las especialidades médicas, proporcionando mejores resultados sin efectos secundarios para el paciente “.

 

Para su práctica se requiere que “la persona responsable de su aplicación tenga un buen conocimiento de esta práctica médica.”

 

Por lo tanto la ozonoterapia ha sido autorizado para su aplicación en todas las especialidades y enfermedades, tanto en el sector público y privado. Requisito: El que la aplique debe “tener un buen conocimiento de esta práctica médica.”

 

Información proporcionada por el Dr. Iliakis Emmanouil (MD., PhD. Cirujano ortopédico).

 

Presidente de la Asociación Científica griega de Oxígeno-Ozonoterapia.

 

Siguenos en Facebook

 

 

en 12 Diciembre 2016

La Habana, Cuba.  El pasado 25 de noviembre de 2016  se llevó a cabo el “8vo. CURSO TEÓRICO-PRÁCTICO: "Infiltración intradiscal y otras vías de aplicación del ozono en el tratamiento y  rehabilitación de las enfermedades del raquis".

Leer mas
en 10 Noviembre 2016

ABSTRACT:

 

Objective(s): Cutaneous Leishmaniasis is a common and endemic disease in Khorasan province in North‐East of Iran. The pentavalant antimony (Sb V) is the mainstay of treatment that has many side effects and resistance to the drug has been reported. The microbicidal effect of ozone was proven in different microorganisms. Since there is no study in this respect and to achieve a low cost and effective treatment, we decided to evaluate the efficacy of ozone against promastigotes of Leishmania major, in vitro.

 

Materials and Methods: Ozonated olive oil was prepared after production of ozone by bubbling ozone‐oxygen gas produced by ozone generator through olive oil until it solidified. Promastigotes of L. major were cultivated in two phasic media. After calculation of the number of promastigotes, they were incubated with ozonated olive oil (0, 0.626, 0.938, 1.25, 2.5, 5, 10 mcg/ml) at 28 °c for 24 hr. Parasites survival percentage was evaluated using MTS and microscopic assay, and then compared with Glucantime and non‐ozonated olive oil.

 

Results: According to the results, there were significant differences in parasites survival percentage between ozonated olive oil and non‐ozonated olive oil, at similar concentrations (P<0.001). Ozonated olive oil was more effective than Glucantime. According to MTS results, Glucantime and ozonated olive oil gel concentrations that are required to inhibit the growth of L. major promastigotes by 50% (IC50), were 165 and 0.002 mg/ml, respectively.

 

Conclusion: Ozonated olive oil has in vitro activity against the promastigotes of L. major and this effect is dose dependent.

Attachments:
Download this file (2015 Aceite Oliva Leishmania.pdf)Adjunto[ ]524 kB
en 09 Noviembre 2016

AIM: to evaluate the results of combined treatment of thromboangiitis obliterans with severe lower limb ischemia using prolonged epidural anaesthesia and autohemotherapy with ozone.

Leer mas
en 09 Noviembre 2016

Introduction. A number of studies suggest that oxygen-ozone therapy may have a role in the treatment of chronic, nonhealing, or ischemic wounds for its disinfectant and antibacterial properties. Nonhealing wounds are a significant cause of morbidity. Here we present a case of subcutaneous oxygen-ozone therapy used to treat a nonhealing postoperative wound in a young man during a period of 5 weeks. Case Presentation. A 46-year-old man had a motorcycle accident and underwent amputation of the right tibia and fibula. At the discharge he came to our attention to start rehabilitation treatment. At that time the wound was ulcerated but it was afebrile with no signs of inflammation and negativity to blood tests. At 2 months from the trauma despite appropriate treatment and dressing, the wound was slowly improving and the patient complained of pain. For this reason in addition to standard dressing he underwent oxygen-ozone therapy. After 5 weeks of treatment the wound had healed. Conclusion. In patients with nonhealing wounds, oxygen-ozone therapy could be helpful in speeding the healing and reducing the pain thanks to its disinfectant property and by the increase of endogenous oxygen free radicals’ scavenging properties. Compared to standard dressing and other treatments reported in the literature it showed a shorter time of action.

en 09 Noviembre 2016

Melanoma is a cancer associated with melanocytes of epidermis. There has been a consistent increase in the number of melanoma patients because of the depletion of the ozone layer which makes it of paramount importance to explore the immunogenic potential of various peptides in melanoma therapy. In the current study, a mutated decapeptide (ELAGIGILTV) epitope ID 12941 was taken from the melanoma antigen recognized by T-cells. This epitope displayed relatively better affinity for histocompatibility leukocyte antigen influencing the proliferation of cytotoxic T-cells. Immunogenicity of the oligopeptide can be further intensified by its simultaneous binding to the programmed death receptor of the T lymphocytes. We have used the molecular dynamics (MD) simulation approach to reveal the dynamics of the decapeptide and its consequences to immunogenic effects. The dynamics have ensembled various conformations of the peptide which have been clustered in their representative conformers. During the dynamics, the peptide was found to fold to its conformation with a minimum free energy. Moreover, multiple analysis of the MD trajectory has provided many physiochemical features involved in the biological activity to improve the immunogenicity of this antigenic peptide. The manuscript concludes by proposing this decapeptide as a potential vaccine for the melanoma cancer.